Targeting of ARID1A-deficient cancers by exploiting a newly identified metabolic vulnerability
Targeting of ARID1A-deficient cancers by exploiting a newly identified metabolic vulnerability
Driver mutations of the ARID1A gene are common in gynecological cancers (~35-55% of endometrial and non-serous ovarian cancers)
Dr. Gloria Huang’s lab at Yale discovered that ARID1Amutated cancers are hypersensitive to inhibitors of de novo pyrimidine synthesis, which suppress proliferation and induce DNA damage in ARID1Amutated cancer cells
Pyrimidine synthesis inhibitors (e.g., teriflunomide) and DNA damage repair inhibitors (e.g. ATR inhibitors) are potently synergistic and selectively target ARID1A-mutated cancers
Combination treatment with inhibitors of pyrimidine synthesis and DNA damage repair induces tumor regression in patient-derived xenograft (PDX) models of ARID1A-mutated human cancer
